Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) has agreed a trade-in deal with the University of Kansas Medical Center (KUMC) for a new clinical-grade Xenon MRI hyperpolariser system.
KUMC, a leading academic centre in xenon MRI research, will exchange its existing hyperpolariser for the latest FDA-approved system provided by Polarean.
The new equipment will support KUMC's studies in areas such as asthma, cystic fibrosis, long Covid, pulmonary hypertension, interstitial lung disease, and scleroderma.
KUMC's Dr Peter Niedbalski recently received a grant to lead a multi-centre study using xenon MRI to explore the structural causes of low lung function and respiratory symptoms in young adults.
Polarean plans to install the new technology later this year, collaborating with KUMC to enhance clinical imaging and support NIH-funded research and pharmaceutical-sponsored trials.
"The team at KUMC has been a valued champion of our pulmonary functional Xenon MRI platform technology for a number of years, pioneering its use across multiple disease areas with their research-grade hyperpolariser," said Polarean CEO Christopher von Jako.
"We are delighted to see KUMC upgrading its hyperpolariser as part of its broader expansion of pulmonary imaging capabilities. This underscores the growing importance that top-tier institutions are placing on Xenon MRI technology."